dc.contributor.author | Kaya M.O. | |
dc.contributor.author | Demirci T. | |
dc.contributor.author | Ozdemir O. | |
dc.contributor.author | Calisir U. | |
dc.contributor.author | Sonmez F. | |
dc.contributor.author | Arslan M. | |
dc.date.accessioned | 2023-03-14T20:29:00Z | |
dc.date.available | 2023-03-14T20:29:00Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1054-2523 | |
dc.identifier.uri | https://doi.org/10.1007/s00044-023-03029-7 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14002/1551 | |
dc.description.abstract | The novel sulfonamide substitute 1,4-dihydropyridine derivatives were synthesized by the method of Hantzsch reaction. They have been characterized by FT-IR spectroscopy, 1H-NMR, 13C-NMR, and elemental analysis. PON1 which is an antioxidant enzyme has important functions in cardiovascular systems. The enzyme has been purified using a two-step method such as ammonium sulfate precipitation and sepharose-4B-l-tyrosine-9-aminophenanthrene hydrophobic interaction chromatography. The results demonstrated that all the synthesized compounds inhibited PON1 enzyme. The best inhibition effect was observed in compound (1) for PON1 enzyme (IC50: 8.04 µM, Ki: 5.43 µM). The free radical scavenging for PON1 was discovered as 20.16 mg/mL, while drug score value was reported as 0.13 for compound (1). Furthermore, the lowest binding energy (?1.31 kcal/mol) determined by molecular docking for PON1 enzyme and the lowest LUMO-HOMO gap (?E = 3.12 eV) were calculated for compound (1). © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | Medicinal Chemistry Research | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | 1,4-dihydropyridine | en_US |
dc.subject | Drug score | en_US |
dc.subject | Inhibition | en_US |
dc.subject | Molecular docking | en_US |
dc.subject | PON1 | en_US |
dc.title | Synthesis, inhibition effects, molecular docking and theoretical studies as Paraoxonase 1 (PON1) inhibitors of novel 1,4-dihydropyridine substituted sulfonamide derivatives | en_US |
dc.type | article | en_US |
dc.department | Belirlenecek | en_US |
dc.identifier.doi | 10.1007/s00044-023-03029-7 | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 55342808300 | |
dc.authorscopusid | 37099630300 | |
dc.authorscopusid | 58119775900 | |
dc.authorscopusid | 57192316949 | |
dc.authorscopusid | 54421145000 | |
dc.authorscopusid | 57203542863 | |
dc.identifier.scopus | 2-s2.0-85149012757 | en_US |